Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Thrive Bioscience, Inc. operates in the Computing & Software technology area. The company currently has 3 pending office actions. These 3 actions are distributed among 3 distinct examiners. Furthermore, the matters are located in 3 distinct art units. This indicates that each pending case is being evaluated by a different examiner in a different technical section of the patent office, reflecting variety within their computing and software filings.
GURMU, MULUEMEBET is the busiest examiner for the company, with 1 pending office action. This examiner is one of the 3 distinct examiners currently reviewing the company's applications. The presence of 3 distinct art units and 3 distinct examiners means that the company's prosecution efforts are split between three separate technical and personnel environments. Practitioners should tailor their strategies to the specific requirements of each of the 3 distinct art units involved in these pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GURMU, MULUEMEBET | 1 | 80.2% | +17.5% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18539249 | CELL MAINTAINER FOR AUTOLOGOUS CELL THERAPY PRODUCTION | NICOL, ALEXANDER W | 34d |
| 19038312 | Method and system for identifying a cell line during incubation of the cell line | GURMU, MULUEMEBET | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18539249 | CELL MAINTAINER FOR AUTOLOGOUS CELL THERAPY PRODUCTION | NICOL, ALEXANDER W | 34d |
| 19038312 | Method and system for identifying a cell line during incubation of the cell line | GURMU, MULUEMEBET | — |
| Art Unit | Apps |
|---|---|
| 2163 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19038312 | Method and system for identifying a cell line during incubation of the cell line | GURMU, MULUEMEBET | 2163 | §101§103 | Non-Final OA | — | Pending | Jan 27, 2025 |
| 18539249 | CELL MAINTAINER FOR AUTOLOGOUS CELL THERAPY PRODUCTION | NICOL, ALEXANDER W | 1634 | §102§103Other | Non-Final OA | 34d | Pending | Dec 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial